The amount of the deal was not disclosed. Previously the lead investor in a Series B funding round for Context Matters last fall, DGR’s acquisition and planned integration of Context Matters aims to reinforce its global market access portfolio by combining the novel Context Matters data model, which links global regulatory and health technology assessment data to detailed clinical trial data, with its existing suite of products and services.
Led by Yin Ho, M.D., M.B.A., Founder and CEO, Context Matters provides pharmaceutical and biotechnology companies with tools to improve the process of valuing drug therapies, to achieve optimal reimbursement for their innovation. The Context Matters Market Access Platform (MAP) defines a new product category for global drug valuation—a configurable technology platform linking drug development and market data through a model making comparative analysis and contextual views possible to establish reimbursement and market access.
FinSMEs
17/08/2017